**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 50956**

**Manuscript Type: ORIGINAL ARTICLE**

***Basic Study***

**MicroRNA-30c inhibits pancreatic cancer cell proliferation by targeting twinfilin 1 and indicates a poor prognosis**

Sun LL *et al.* MiR-30c inhibits pancreatic cancer cell proliferation by targeting TWF1

Lu-Lu Sun, Ming Cheng, Xiao-Dong Xu

**Lu-Lu Sun,** Department of Ultrasonography, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China

**Ming Cheng,** Department of Information, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China

**Xiao-Dong Xu,** Department of Breast Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China

**ORCID number:** Lu-Lu Sun (0000-0001-6659-9309); Ming Cheng (0000-0001-5220-963X); Xiao-Dong Xu (0000-0002-9822-3725).

**Author contributions:** Sun LL andXu XD designed the research and critically revised the manuscript for important intellectual content; Cheng M helped with the statistical analysis; all authors read and approved the final manuscript paper.

**Supported by** the National Nature Science Foundation of China, No. 61802350.

**Institutional review board statement:** This study was approved by the institutional review board of Zhengzhou University.

**Institutional animal care and use committee statement:** All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of Zhengzhou University.

**Conflict-of-interest statement:** All authors declare no competing financial interests.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author:** **Xiao-Dong Xu, PhD, Professor,** Department of Breast Surgery, the First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe East Road, Zhengzhou 450000, Henan Province, China. tjxuxiaodong@163.com

**Telephone:** +86-371-66279162

**Fax:** +86-371-66279162

**Received:** August 19, 2019

**Peer-review started:** August 19, 2019

**First decision:** September 10, 2019

**Revised:** October 16, 2019

**Accepted:** November 1, 2019

**Article in press:** November 1, 2019

**Published online:** November 14,2019

**Abstract**

***BACKGROUND***

Studies have reported that microRNA-30c (miR-30c) has vital functions in the development and progression of multiple cancers.

***AIM***

To investigate the clinical significance and role of miR-30c in pancreatic cancer.

***METHODS***

MiR-30c and twinfilin 1 (TWF1) expression levels were analyzed in Gene Expression Omnibus datasets and validated in human pancreatic cancer by quantitative real-time polymerase chain reaction (RT-qPCR). The effects of miR-30c on pancreatic cancer cell growth, apoptosis, and cell cycle were evaluated by CCK-8 and flow cytometry assays. Furthermore, the *in vivo* effects were investigated using a subcutaneous xenograft experiment. Target gene prediction software and luciferase reporter assays were used to identify TWF1 as a direct target of miR-30c.

***RESULTS***

The expression of miR-30c was significantly decreased in pancreatic cancer tissues and associated with survival. Gain- and loss-of-function assays showed that miR-30c suppressed pancreatic cancer cell proliferation *in vitro* and *in vivo*. RT-qPCR, Western blot, and luciferase reporter assays showed that miR-30c directly targeted TWF1. The expression level of miR-30c was negatively correlated with TWF1 expression in pancreatic cancer tissues. Furthermore, the effects of ectopic miR-30c were rescued by TWF1 overexpression.

***CONCLUSION***

Our results identified the role of the miR-30c/TWF1 axis in pancreatic cancer progression and demonstrated that miR-30c might serve as a prognostic biomarker and therapeutic target for pancreatic cancer.

**Key words:** Pancreatic cancer; MicroRNA-30c; Proliferation; Twinfilin 1

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Studies have shown that miR-30c exerts vital roles in the oncogenesis of various cancers. However, its expression and role in pancreatic cancer remain unknown. In this study, the expression levels of miR-30c and twinfilin 1 were mined in Gene Expression Omnibus datasets and detected in clinical samples. The relationship of miR-30c expression with clinicopathological factors of pancreatic cancer patients was analyzed. The effect of miR-30c on pancreatic cancer cell proliferation and the underlying regulatory mechanism were investigated. Our study suggested that miR-30c may serve as a prognostic biomarker and therapeutic target for pancreatic cancer.

Sun LL, Cheng M, Xu XD. MicroRNA-30c inhibits pancreatic cancer cell proliferation by targeting twinfilin 1 and indicates a poor prognosis. *World J Gastroenterol* 2019; 25(42): 6311-6321

**URL:** https://www.wjgnet.com/1007-9327/full/v25/i42/6311.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v25.i42.6311

**INTRODUCTION**

Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant gastrointestinal cancers and the prognosis of PDAC patients is very poor[1]. Although diagnostic methods and therapeutic strategies have been substantially improved, the clinical outcome of pancreatic cancer patients remains poor[2]. Therefore, it is necessary and urgent to understand the molecular mechanisms of pancreatic cancer development and thus identify new precise therapeutic strategies.

MicroRNAs (miRNAs), small noncoding RNAs of 19-22 nucleotides in length, are known to suppress gene expression by binding to their 3’-untranslated regions (3’-UTRs)[3]. Studies have shown that miRNAs are involved in tumor oncogenesis and progression of multiple cancers[4-6]. MiR-30c is one of members of the miR-30 family, which includes miR-30a, miR-30b, miR-30c, miR-30d, miR-30e, and miR-30f[7]. Studies indicate that loss of miR-30c contributes to various malignancies, including gastric cancer, ovarian cancer, and hepatocellular carcinoma[8-10]. However, the expression and role of miR-30c in pancreatic cancer have not been determined.

Twinfilin 1 (TWF1), an actin-binding protein, regulates diverse aspects of actin dynamics[11]. This protein was shown to promote cardiac hypertrophy[12]. The miR-206/TWF1/MKL1-SRF/IL11 signaling pathway inhibited the stemness and metastasis of breast cancer cells[13]. TWF1 regulated breast cancer cell invasion by STAT3 phosphorylation[14]. Furthermore, TWF1 promoted human breast tumor chemotherapy resistance[15]. Overexpression of TWF1 was identified as an inferior prognosis indicator in lung adenocarcinoma[16]. The findings of these studies suggest that TWF1 is a putative driver gene in cancers.

In the present study, we investigated the expression of miR-30c and its relationship with clinical features in pancreatic cancer. In addition, the function of miR-30c in pancreatic cancer was explored, as well as the potential molecular mechanisms. Our findings suggest that miR-30c might be a potential therapeutic target for pancreatic cancer.

**MATERIALS AND METHODS**

***Tissue samples and ethics statement***

Fresh human pancreatic cancer tissues and adjacent normal tissues were collected from 40 patients who received pancreaticoduodenectomy from 2012 to 2013 at the First Affiliated Hospital of Zhengzhou University (ZZU). All tissues were stored in liquid nitrogen. The patients did not receive chemotherapy or radiotherapy before surgery. All patients were independently diagnosed with adenocarcinoma by two experienced pathologists. All samples were collected with informed written consent from all patients, and our study was approved by the Ethical Committee of Zhengzhou University.

***Cell culture and transfection***

Pancreatic cancer cell lines (BxPC-3, Capan-2, Mia PaCa-2, Panc-1, and SW1990) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, United States). An immortalized human pancreatic ductal epithelial cell line (HPDE) was obtained from the Cell Repository, Chinese Academy of Sciences (Shanghai, China). All cell lines in this study were authenticated by short tandem repeat DNA profiling and cultured according to the manufacturer’s instructions. MiR-30c mimics, miR-30c inhibitors, and negative control sequences were purchased from GeneChem (Shanghai, China). Lentiviruses overexpressing miR-30c and the lentivirus control were produced by GeneChem (Shanghai, China). Transfection of the recombinant lentiviruses was performed according to the supplier’s instructions. Transfection efficiency was monitored by quantitative real-time polymerase chain reaction (RT-qPCR), which was independently repeated at least three times.

***Cell proliferation assay***

After treatment, cells were seeded into 96-well plates (1 × 103 cells per well). Cell viability was detected by Cell Counting Kit-8 assays (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer’s instructions.

***Apoptosis assay***

Cells were transfected with control, miR-30c mimics, or miR-30c inhibitors. After transfection for 48 h, cells were harvested and stained with an Annexin V/FITC and propidium iodide Apoptosis Detection Kit (MultiSciences, Hangzhou, China) according to the manufacturer’s protocol. The stained cells were then detected using the fluorescence-activated cell sorting (FACS) Caliber system (BD Immunocytometry Systems, San Jose, CA, United States).

***Cell cycle analysis***

Cells were transfected with control, miR-30c mimics, or miR-30c inhibitors in six-well plates. After treatment for 48 h, cells were washed, harvested, and stained according to the instructions of the Cell Cycle Analysis Kit (Multi Sciences, Hangzhou, China). Next, the cells were analyzed using the FACS Caliber system. The percentages of the cells in each phase were determined.

***RNA extraction and RT-qPCR***

Total RNA from each group of cells was extracted using TRIzol reagent (Invitrogen, United States) and synthesized into cDNA *via* a reverse transcription kit (TaKaRa, Dalian, China) according to the manufacturer’s instructions**.** Theprimers used are listed below: MiR-30c: forward 5'-GCCGCTGTAAACATCCTACACT-3' and reverse 5'-GTGCAGGGTCCGAGGT-3'; U6: forward 5’-CTCGCTTCGGCAGCACA-3’ and reverse 5’-AACGCTTCACGAATTTGCGT-30; TWF1: forward 5’-ACGTGGGTGTGGACACT AAG-3’ and reverse 5’-GGGAATCCTCTTTGGC AAATCTT-3’; and GAPDH: forward 5’-CGTGGGCCGCCCTAGGCACCA-3’ and reverse 5’-TTG GCTTAGGGTTCAGGGGGG-3’. U6 was used as the miRNA internal control and the housekeeping gene GAPDH was used as the mRNA internal control. RT-qPCR was performed with an ABI 7500 system (Applied Biosystems, United States) according to the manufacturer’s instructions.

***Western blot analysis***

Western blot analysis was carried out as previously described ([Lai *et al*[5], 2017](#_ENREF_8)). Antibodies against human TWF1 were purchased from Cell Signaling Technology (Beverly, MA, United States). Antibodies against human GAPDH and secondary antibodies were purchased from Boster (Wuhan, China).

***Immunohistochemistry (IHC)***

IHC analysis was performed as previously described ([Lai *et al*[5], 2017](#_ENREF_8)). Antibodies for IHC against human TWF1 were purchased from Abcam (Cambridge, MA, United States). Antibodies against human Ki67 were purchased from Boster (Wuhan, China). Semi-quantitative scoring of immunohistochemical staining was performed using the H-score method, and stain score was calculated as intensity × positive rate.

***Targeting gene prediction and gene expression omnibus (GEO) data***

Bioinformatics analysis was performed to predict target genes of miR-30c with TargetScan, miRDB, and miRTarBase. The results indicated that TWF1 is the strongest potential target of miR-30c. MiR-30c expression in Gene Expression Omnibus (GEO) datasets was analyzed with GEO2R. Expression levels were log2-transformed and assessed by an unpaired *t* test between the tumor and control groups.

***Dual-luciferase reporter assay***

Wild-type and mutant 3’-UTRs of TWF1 luciferase reporter vectors were purchased from Promega (Madison, WI, United States). After incubation for 48 h, a dual-luciferase reporter assay system (Promega) was used to measure the luciferase activity. Relative luciferase activity was normalized by the ratio of firefly and Renilla luciferase signals.

***Animal experiments***

Ten 4-6-week-old male nude mice were purchased from HFK Bioscience (Beijing, China) and bred in specific pathogen-free conditions. After treatment, 2 × 106 pancreatic cancer cells were injected in the axilla subcutaneously in each group. Tumor volume was measured using calipers every week and calculated as length × width2 × 0.5. Five weeks later, mice were sacrificed and tumors were removed, weighed, and further analyzed. The animal study was conducted in accordance with NIH animal use guidelines and approved by the Animal Care Committee of Zhengzhou University.

***Statistical analysis***

A two-tailed paired *t*-test was used to analyze the expression difference of miR-30c and TWF1 between cancerous tissues and adjacent noncancerous tissues. Paired or unpaired *t*-test was used to analyze the expression difference between two groups. The association of miR-30c expression with clinicopathological parameters was analyzed using chi-square tests. Data analyses were performed with SPSS 17.0 (SPSS Inc., Chicago, IL, United States) and presented with GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, United States). All experiments were carried out at least three times. *P* < 0.05 was defined as statistically significant.

**RESULTS**

***MiR-30c downregulation in pancreatic cancer is associated with poor patient prognosis***

To study the expression of miR-30c in human pancreatic cancer, we first analyzed two GEO datasets GSE24279 and GSE60978. The results showed that miR-30c levels were frequently downregulated in pancreatic cancer tissue samples compared with nontumor tissues (Figure 1A and B). Then, we validated the expression of miR-30c in 40 matched pancreatic cancer patient samples and the corresponding adjacent nontumor tissues by RT-qPCR. MiR-30c was also downregulated in pancreatic cancer (Figure 1C). Then, we stratified all patients into miR-30c high and miR-30c low groups by the median of miR-30c expression and analyzed the clinical information. Pancreatic cancer patients with low miR-30c expression had poorer survival status than those with high miR-30c expression (median survival: 12 mo *vs* 19.2 mo; log-rank test, *P* < 0.05; Figure 1D). Meanwhile, miR-30c expression levels in tumors were significantly correlated with tumor stage (American Joint Committee on Cancer 7th edition) but not with sex, age, or tumor grade of pancreatic cancer (Table 1). Collectively, these data indicate that miR-30c is downregulated in pancreatic cancer and correlates with a poor prognosis.

***MiR-30c inhibits the growth of pancreatic cancer cells in vitro***

To investigate the biological role of miR-30c *in vitro*, we examined miR-30c expression in five pancreatic cancer cell lines (BxPC-3, Capan-2, Mia PaCa-2, Pan-1, and SW1990) and HPDE cell line by RT-qPCR (Figure 2A). Then, BxPC-3 and Mia PaCa-2 cells were transfected with control, miR-30c mimics, or miR-30c inhibitors. The transfection efficiency in the two cell lines was validated by RT-qPCR (Figure 2B). The CCK-8 assays showed that the proliferation of BxPC-3 and Mia PaCa-2 cells was markedly decreased after transfection with miR-30c mimics compared with the control group (Figure 2C and D). The proliferation ability of both cell lines was markedly increased after transfection with miR-30c inhibitors (Figure 2C and D). The above results revealed that miR-30c suppressed the proliferation of pancreatic cancer cells, which is associated with cell apoptosis and cell cycle processes. Therefore, we studied whether miR-30c could regulate cell apoptosis and the cell cycle by flow cytometry. Flow cytometry analysis revealed that gain of miR-30c markedly increased the cell apoptosis rate, whereas loss of miR-30c decreased the apoptosis rate (Figure 2E). Cell cycle results showed that gain of miR-30c significantly increased the percentage of G1 phase cells, and loss of miR-30c decreased the proportion of cells in G1 phase (Figure 2F). Taken together, these results indicate that miR-30c represses pancreatic cancer cell proliferation by inducing apoptosis and cell cycle arrest *in vitro*.

***TWF1 is a direct target of miR-30c***

To further explore the potential downstream targets of miR-30c, three online bioinformatics tools (TargetScan, miRDB, and miRTarBase) were used, and the prediction results were comprehensively analyzed (Figure 3A). There were 55 predicted targets for TargetScan, 849 for miRDB, and 521 for miRDB. Five predicted genes (TWF1, RAD23B, S100PBP, MIA3, and VPS33A) in common were identified. We focused on the actin-binding protein TWF1, which regulates diverse aspects of actin dynamics. We first transfected control or miR-30c mimics into pancreatic cancer cells, and then, TWF1 expression levels were detected by RT-qPCR and Western blot analyses. The results showed that re-expression of miR-30c inhibited the mRNA and protein expression of TWF1 (Figure 3B and C). Then, wild-type or mutant TWF1 luciferase reporter vector was constructed (Figure 3D). After transfection, we found that miR-30c mimics dramatically inhibited the luciferase activity of wild-type TWF1, whereas the luciferase activity of mutant TWF1 showed no significant difference (Figure 3E). Collectively, these results demonstrate that TWF1 is a direct target of miR-30c.

***Overexpression of miR-30c inhibits tumor growth in vivo***

To further evaluate the oncogenic role of miR-30c *in vivo*, xenograft tumor models were established in BALB/C nude mice using BxPC-3 cells transfected with lentivirus-control or lentivirus-miR-30c vector. As shown in Figure 4A, all the nude mice developed xenograft tumors 5 wk after injection. Furthermore, the average tumor volume and weight of the miR-30c overexpression group were significantly smaller than those in the control group (Figure 4B and C). IHC analysis showed that tumors derived from lentivirus-miR-30c group showed weaker staining of Ki-67 than those in the control group (Figure 4D). Interestingly, tumors derived from the lentivirus-miR-30c overexpression group also showed weaker staining for the target gene TWF1 than those in the control group (Figure 4D). The xenograft tumor tissues were analyzed to verify miR-30c and TWF1 expression using RT-qPCR, which showed similar results to the IHC results (Figure 4E and F). These data suggest that re-expression of miR-30c inhibits tumor growth *in vivo*.

***TWF1 overexpression abolishes the effects of miR-30c loss***

We demonstrated that the re-expression of miR-30c suppressed the proliferation of pancreatic cancer cells and inhibited TWF1 expression. To further confirm whether the effect of miR-30c in PDAC cells is mediated by regulation of TWF1, we overexpressed TWF1 in BxPC-3 and Mia PaCa-2 cells transfected with stable lentivirus-miR-30c. Compared with controls, cells transfected with lentivirus-TWF1 showed significantly higher expression of TWF1 at both the mRNA and protein levels (Figure 5A-C). CCK-8 assays revealed that ectopic TWF1 expression effectively reversed the inhibition of proliferation induced by miR-30c overexpression (Figure 5D and E). Apoptosis analysis showed that ectopic TWF1 expression effectively reversed the promotion of apoptosis induced by miR-30c overexpression (Figure 5F). Similarly, TWF1 upregulation significantly reversed the inhibitory effects of miR-30c induced cell cycle progression (Figure 5G). TWF1 expression was detected in 40 paired pancreatic specimens by RT-qPCR. TWF1 was increased in pancreatic cancer tissues (Figure 5H). Moreover, the mRNA levels of TWF1 and miR-30c exhibited a significant inverse correlation as shown by the Pearson correlation test in pancreatic cancer tissues (Figure 5I). Taken together, these results reveal that miR-30c acts as a negative regulator in the growth of pancreatic cancer cells, which is at least partly dependent on the modulation of TWF1.

**DISCUSSION**

Sustained proliferation is a hallmark of cancer and is regulated by multiple molecules, including miRNAs[17]. The roles and molecular mechanisms of miRNAs in tumorigenesis have attracted increased attention. MiR-30c was proven to be a critical regulator in the malignant progression of various cancers. However, the clinical significance and biological role of miR-30c in pancreatic cancer remain unknown. Our results showed that TWF1 is a direct target of miR-30c in pancreatic cancer. Furthermore, ectopic overexpression of miR-30c blocked pancreatic cancer cell proliferation *in vitro* and *in vivo*.

MiR-30c has been identified to be tumor suppressive and downregulated in various cancers. In esophageal squamous cell carcinoma, downregulated miR-30c inhibited biological behaviors and epithelial-mesenchymal transition of ESCC by directly targeting SNAI1[18]. In breast cancer, micRNA-30c negatively regulated collagen triple helix repeat containing-1 and suppressed cell proliferation and metastasis[5]. MiRNA-30c inhibited proliferation of non-small cell lung cancer cells by targeting Rab18[19]. In our study, we found that downregulation of miR-30c occurred widely in pancreatic cancer, and predicted a poor prognosis. Similarly, miR-30c was downregulated in five pancreatic cancer cell lines compared with HPDE. Consistent with these findings, experiments *in vitro* and *in vivo* showed that re-expression of miR-30c significantly inhibited cell proliferation by inducing apoptosis and G1-phase arrest. Bioinformatics prediction analysis was carried out to search for potential targets of miR-30c and identified TWF1 as a promising target. TWF1 was shown to be a target of miR-30c. Furthermore, rescue experiments showed that enforced overexpression of TWF1 could strongly restore the proliferation of miR-30c-overexpressing cells. The TWF1 mRNA level exhibited an inverse correlation with the level of miRNA-30c in both pancreatic cancer patient tissues and subcutaneous tumors derived from nude mice. We concluded that miR-30c might exert its effect by influencing TWF1 expression to inhibit pancreatic cancer proliferation.

In this study, we provide evidence that miR-30c functions as a tumor-suppressive gene through direct inhibition of TWF1 in pancreatic cancer. Our results suggest that miR-30c might represent a potential therapeutic target for the treatment of human pancreatic cancer.

**ARTICLE HIGHLIGHTS**

***Research background***

Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant gastrointestinal cancers worldwide. Current diagnostic methods and therapeutic strategies are very limited, and the prognosis of pancreatic cancer patients remains poor. To understand the molecular mechanisms of pancreatic cancer development is necessary and urgent. Little is known regarding miR-30c expression and its role in the progression of PDAC.

***Research motivation***

Our study will provide a new therapeutic target for pancreatic cancer.

***Research objectives***

To study the expression, role, and target gene of miR-30c in pancreatic cancer.

***Research methods***

We detected the expression levels of miR-30c and twinfilin 1 (TWF1) in Gene Expression Omnibus datasets and validated in clinical samples by quantitative real-time polymerase chain reaction. The relationship of miR-30c expression with clinicopathological factors of pancreatic cancer patients was analyzed. The effect and mechanism miR-30c on pancreatic cancer cell proliferation were investigated *in vitro* and *in vivo*. Assays were performed to explore potential target gene TWF1 of miR-30c in pancreatic cancer.

***Research results***

In the present study, we found that miR-30c was downregulated and associated with a poor prognosis in pancreatic cancer patients. We showed that re-expression of miR-30c reduced pancreatic cancer cell proliferation *in vitro* and *in vivo* by targeting TWF1. Meanwhile, overexpression of TWF1 abolished the effects of miR-30c in pancreatic cancer.

***Research conclusions***

MiR-30c is downregulated and promotes the proliferation of pancreatic cancer cells by targeting TWF1. Overexpression of TWF1 abolishes the effects of miR-30c.

***Research perspectives***

This study provides insight into the role of miR-30c in promoting pancreatic cancer development by targeting TWF1. MiR-30c might be a new therapeutic target for pancreatic cancer.

**REFERENCES**

1 **Miller KD**, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. *CA Cancer J Clin* 2016; **66**: 271-289 [PMID: 27253694 DOI: 10.3322/caac.21349]

2 **McGuigan A**, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. *World J Gastroenterol* 2018; **24**: 4846-4861 [PMID: 30487695 DOI: 10.3748/wjg.v24.i43.4846]

3 **Chen Y**, Zhao ZX, Huang F, Yuan XW, Deng L, Tang D. MicroRNA-1271 functions as a potential tumor suppressor in hepatitis B virus-associated hepatocellular carcinoma through the AMPK signaling pathway by binding to CCNA1. *J Cell Physiol* 2019; **234**: 3555-3569 [PMID: 30565670 DOI: 10.1002/jcp.26955]

4 **Fu Y**, Liu X, Chen Q, Liu T, Lu C, Yu J, Miao Y, Wei J. Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4. *J Exp Clin Cancer Res* 2018; **37**: 130 [PMID: 29970191 DOI: 10.1186/s13046-018-0807-2]

5 **Lai YH**, Chen J, Wang XP, Wu YQ, Peng HT, Lin XH, Wang WJ. Collagen triple helix repeat containing-1 negatively regulated by microRNA-30c promotes cell proliferation and metastasis and indicates poor prognosis in breast cancer. *J Exp Clin Cancer Res* 2017; **36**: 92 [PMID: 28697793 DOI: 10.1186/s13046-017-0564-7]

6 **Liu Y**, Wu L, Li K, Liu F, Wang L, Zhang D, Zhou J, Ma X, Wang S, Yang S. Ornithine aminotransferase promoted the proliferation and metastasis of non-small cell lung cancer via upregulation of miR-21. *J Cell Physiol* 2019; **234**: 12828-12838 [PMID: 30549035 DOI: 10.1002/jcp.27939]

7 **Mao L**, Liu S, Hu L, Jia L, Wang H, Guo M, Chen C, Liu Y, Xu L. miR-30 Family: A Promising Regulator in Development and Disease. *Biomed Res Int* 2018; **2018**: 9623412 [PMID: 30003109 DOI: 10.1155/2018/9623412]

8 **Cao JM**, Li GZ, Han M, Xu HL, Huang KM. MiR-30c-5p suppresses migration, invasion and epithelial to mesenchymal transition of gastric cancer via targeting MTA1. *Biomed Pharmacother* 2017; **93**: 554-560 [PMID: 28686969 DOI: 10.1016/j.biopha.2017.06.084]

9 **Han X**, Zhen S, Ye Z, Lu J, Wang L, Li P, Li J, Zheng X, Li H, Chen W, Li X, Zhao L. A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells. *Cell Physiol Biochem* 2017; **41**: 973-986 [PMID: 28222434 DOI: 10.1159/000460618]

10 **Liu D**, Wu J, Liu M, Yin H, He J, Zhang B. Downregulation of miRNA-30c and miR-203a is associated with hepatitis C virus core protein-induced epithelial-mesenchymal transition in normal hepatocytes and hepatocellular carcinoma cells. *Biochem Biophys Res Commun* 2015; **464**: 1215-1221 [PMID: 26210453 DOI: 10.1016/j.bbrc.2015.07.107]

11 **Ydenberg CA**, Johnston A, Weinstein J, Bellavance D, Jansen S, Goode BL. Combinatorial genetic analysis of a network of actin disassembly-promoting factors. *Cytoskeleton (Hoboken)* 2015; **72**: 349-361 [PMID: 26147656 DOI: 10.1002/cm.21231]

12 **Li Q**, Song XW, Zou J, Wang GK, Kremneva E, Li XQ, Zhu N, Sun T, Lappalainen P, Yuan WJ, Qin YW, Jing Q. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. *J Cell Sci* 2010; **123**: 2444-2452 [PMID: 20571053 DOI: 10.1242/jcs.067165]

13 **Samaeekia R**, Adorno-Cruz V, Bockhorn J, Chang YF, Huang S, Prat A, Ha N, Kibria G, Huo D, Zheng H, Dalton R, Wang Y, Moskalenko GY, Liu H. miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway. *Clin Cancer Res* 2017; **23**: 1091-1103 [PMID: 27435395 DOI: 10.1158/1078-0432.CCR-16-0943]

14 **Bockhorn J**, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. *Breast Cancer Res Treat* 2013; **137**: 373-382 [PMID: 23224145 DOI: 10.1007/s10549-012-2346-4]

15 **Bockhorn J**, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. *Nat Commun* 2013; **4**: 1393 [PMID: 23340433 DOI: 10.1038/ncomms2393]

16 **Kaishang Z**, Xue P, Shaozhong Z, Yingying F, Yan Z, Chanjun S, Zhenzhen L, Xiangnan L. Elevated expression of Twinfilin-1 is correlated with inferior prognosis of lung adenocarcinoma. *Life Sci* 2018; **215**: 159-169 [PMID: 30391462 DOI: 10.1016/j.lfs.2018.10.067]

17 **Wang J**, Guo XJ, Ding YM, Jiang JX. miR-1181 inhibits invasion and proliferation *via* STAT3 in pancreatic cancer. *World J Gastroenterol* 2017; **23**: 1594-1601 [PMID: 28321160 DOI: 10.3748/wjg.v23.i9.1594]

18 **Ma T**, Zhao Y, Lu Q, Lu Y, Liu Z, Xue T, Shao Y. MicroRNA-30c functions as a tumor suppressor via targeting SNAI1 in esophageal squamous cell carcinoma. *Biomed Pharmacother* 2018; **98**: 680-686 [PMID: 29304493 DOI: 10.1016/j.biopha.2017.12.095]

19 **Zhong K**, Chen K, Han L, Li B. MicroRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18. *BMC Cancer* 2014; **14**: 703 [PMID: 25249344 DOI: 10.1186/1471-2407-14-703]

**P-Reviewer:** Dambrauskas Z, Kleeff J

**S-Editor:** Tang JZ **L-Editor:** Wang TQ **E-Editor:** Zhang YL

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0




**Figure 1 Downregulation of miR-30c and its prognostic significance in pancreatic cancer.** A: MiR-30c expression in the Gene Expression Omnibus (GEO) dataset GSE24279. B: MiR-30c expression in the GEO dataset GSE60978. C: Quantitative real-time polymerase chain reaction detection of the expression of miR-30c in tissues collected at the First Affiliated Hospital of Zhengzhou University. D: Kaplan–Meier analysis of survival of pancreatic cancer patients (*n* = 40). The data are presented as the mean ± standard deviation. *P* < 0.05 was considered statistically significant. e*P* < 0.001 *vs* nontumor group. ZZU: Zhengzhou University.




**Figure 2** **MiR-30c inhibits the growth of pancreatic cancer cell lines *in vitro*.** A: Expression levels of miR-30c in five human pancreatic cancer cell lines and human pancreatic ductal epithelial cell line (HPDE). B: Expression levels of miR-30c in cells transfected with control, miR-30c mimics, or miR-30c inhibitors. C: CCK-8 assays showed distinct differences in proliferation after manipulation of miR-30c in Mia PaCa-2 cells. D: CCK-8 assays showed distinct differences in proliferation after manipulation of miR-30c in BxPC-3 cells. E: Flow cytometry assays were performed to detect the apoptotic rates of cells after transfection. F: Flow cytometric analysis was performed to detect the cell cycle distribution of cells after transfection. All experiments were performed at least three times. The data are presented as the mean ± standard deviation*. P* < 0.05 was considered statistically significant. a*P* < 0.05 *vs* control group; b*P* < 0.01 *vs* control group; e*P* < 0.001 *vs* control group; c*P* < 0.05 *vs* HPDE; d*P* < 0.01 *vs* HPDE.HPDE: Human pancreatic ductal epithelial cell line.



**Figure 3** **Twinfilin 1 is a direct target of miR-30c.** A: Venn diagram showing that miR-30c targets twinfilin 1 (TWF1) by three prediction tool intersections. B: Expression of TWF1 detected by quantitative real-time polymerase chain reaction after control or miR-30c mimics were transfected into pancreatic cancer cells. C: Expression of TWF1 detected by Western blot analysis after control or miR-30c mimics were transfected into pancreatic cancer cells. D: Predicted miR-30c target sequence in the TWF1 3’-UTR based on the TargetScan database. E: Relative luciferase activity of dual-luciferase reporter plasmids carrying wild-type or mutant TWF1 3’-UTR in pancreatic cancer cells cotransfected with control or miR-30c mimics. All experiments were performed at least three times. The data are presented as the mean ± standard deviation. *P* < 0.05 was considered statistically significant. a*P* < 0.05 *vs* mimics group; b*P* < 0.01 *vs* mimics group. Twinfilin 1: TWF1; 3’-UTRs: 3’-untranslated regions; WT: Wild-type; Mut: Mutant.



**Figure 4 Overexpression of miR-30c inhibits tumor growth *in vivo*.** A: Images of the xenograft model from each treated group. B: Tumor growth curves of each treated group in mice (*n* = 5) inoculated with the indicated cells on the indicated days. C: Tumor weight of each treated group. D: H&E staining and immunohistochemistry analysis of Ki-67 and twinfilin 1 (TWF1) in each treated group. Scale bar, 50 μm (red line). E and F: Quantitative real-time polymerase chain reaction analysis of miR-30c and TWF1 expression in xenograft tumors of the indicated group. The data are presented as the mean ± standard deviation. *P* < 0.05 was considered statistically significant. e*P* < 0.001 *vs* control group. TWF1: Twinfilin 1.



**Figure 5 Overexpression of twinfilin 1 abolishes the effects of loss of miR-30c.** A and B: Quantitative real-time polymerase chain reaction (RT-qPCR) was used to determine the expression levels of twinfilin 1 (TWF1). C: Western blot was used to determine the expression levels of TWF1. D and E: CCK-8 assays were used to determine the cell proliferation of different groups. F and G: The apoptosis and cell cycle distribution of pancreatic cancer cells in different groups were investigated by flow cytometry. H: RT-qPCR detection of the expression of TWF1 in tissues collected at The First Affiliated Hospital of Zhengzhou University. I: Negative correlation between the expression levels of miR-30c and TWF1 in pancreatic cancer tissues. The data are presented as the mean ± standard deviation. All experiments were performed at least three times. *P* < 0.05 was considered statistically significant. e*P* < 0.001 *vs* nontumor group; c*P* < 0.05 *vs* miR-30c + TWF1 group. TWF1: Twinfilin 1.

**Table 1** **Characteristics of the subjects enrolled in the miR-30c expression study of pancreatic cancer patients in the Zhengzhou University cohort**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | ***n*** | **High** | **Low** | ***P*-value** |
| Sex | 40 | 20 | 20 | 0.386 |
| Male | 26 | 13 | 13 |  |
| Female | 14 | 5 | 9 |  |
| Age, yr |  |  |  | 0. 972 |
| <50 | 29 | 13 | 16 |  |
| ≥50 | 11 | 5 | 6 |  |
| Grade |  |  |  | <0.05 |
| Low (I and II) | 31 | 20 | 11 |  |
| High (III and IV) | 9 | 6 | 3 |  |
| Stage |  |  |  | 0.842 |
| Early (I and II) | 14 | 8 | 6 |  |
| Late (III and IV) | 26 | 14 | 12 |  |